LONE TREE, Colo., Sept. 11, 2017 /PRNewswire/ -- Zynex, Inc. (ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, announces today that it will be presenting at the Rocky Mountain MicroCap Conference this month sponsored by GVC Capital and Trickle Research in Denver at Coors Field.
GVC and Trickle expect to host approximately 65 investors at its 2017 conference -- mainly buyside portfolio managers and fund managers, analysts, family offices, brokers, and high net worth individual investors looking for growth opportunities in the microcap space.
Current sponsors of the conference are: Corporate Stock Transfer, Hein & Associates LLP, Ibex Investors, Island Stock Transfer, Polsinelli PC, and SMM.Global.
About Zynex
Zynex, founded in 1996, markets and sells its own design of electrotherapy medical devices used for pain management and rehabilitation; and the company's proprietary NeuroMove device designed to help recovery of stroke and spinal cord injury patients. Zynex is also developing a new blood volume monitor for use in hospitals and surgery centers. For additional information, please visit: Zynex.com.
About GVC Capital LLC
GVC Capital LLC is an innovative investment banking firm headquartered in the Denver suburb of Greenwood Village, Colorado. GVC focuses primarily on providing comprehensive investment banking services to underexposed and undervalued microcap companies. Over the past fifteen years, GVC has assisted emerging growth companies in raising in excess of $600 million in over 100 transactions. For more information, visit www.gvccap.com.
About Trickle Research
Trickle Research provides proprietary microcap and smallcap research to our investors and subscribers. Subscriptions to our service are by invitation. If you would like to discuss access to our research please contact Dave Lavigne at Dave@TrickleResearch.com.
Safe Harbor Statement
Certain statements in this release are "forward-looking" and as such are subject to numerous risks and uncertainties. Actual results may vary significantly from the results expressed or implied in such statements. Factors that could cause actual results to materially differ from forward-looking statements include, but are not limited to, the need to obtain additional capital or augment our liquidity in order to continue our business, the success of our international expansion efforts, our ability to engage additional sales representatives and their success, the need to obtain FDA clearance and CE marking of new products, the acceptance of new products as well as existing products by doctors and hospitals, larger competitors with greater financial resources, the need to keep pace with technological changes, our dependence on the reimbursement from insurance companies for products sold or rented to our customers, acceptance of our products by health insurance providers, our dependence on third party manufacturers to produce our goods on time and to our specifications, implementation of our sales strategy including a strong direct sales force, the uncertain outcome of pending material litigation, our ability to up-list to a larger exchange and other risks described in our filings with the Securities and Exchange Commission including the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2016 as well as Forms 10-Q, 8-K and 8-K/A, press releases and the Company's website.
CONTACT INFORMATION
Zynex, Inc. (303) 703-4906
Investor Relations Contact:
Amato And Partners, LLC
Investor Relations Counsel
admin@amatoandpartners.com
Michael Donnelly
Vice President of Investment Banking
GVC Capital LLC
mdonnelly@gvccap.com
(720) 488-4729
Dave Lavigne
Founder/ Senior Analyst
Trickle Research LLC
Dave@TrickleResearch.com
(720) 394-1019
View original content with multimedia:http://www.prnewswire.com/news-releases/zynex-to-present-at-the-rocky-mountain-microcap-conference-in-denver-on-september-25-2017-300516859.html
SOURCE Zynex
